A new stent design called the DynamX Coronary Bioadaptor has shown promise in reducing stent-related adverse events. A trial comparing the Bioadaptor to a traditional drug-eluting stent found significantly lower rates of adverse events after 12 months with the Bioadaptor. The Bioadaptor consists of three strands coated with a resorbable polymer. The unique design allows the stent to adapt to vessel hemodynamics and avoid disrupting vessel function. While the short-term results are promising, experts emphasize the need for longer follow-up to assess the device’s performance over time and determine if any late complications may arise.
Source link